PubRank

Kathleen M Giacomini

Author PubWeight™ 115.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Membrane transporters in drug development. Nat Rev Drug Discov 2010 8.56
2 Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A 2003 5.77
3 Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007 4.47
4 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2011 2.52
5 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006 2.37
6 Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007 2.32
7 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 2.20
8 The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2003 2.06
9 Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 2003 2.03
10 Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006 1.96
11 Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003 1.79
12 cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A 2008 1.62
13 Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002 1.57
14 Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010 1.48
15 Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci 2006 1.48
16 Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 2008 1.47
17 Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet Genomics 2009 1.46
18 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006 1.38
19 Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 2012 1.38
20 Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011 1.35
21 Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 2007 1.33
22 Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. J Med Chem 2011 1.30
23 Renal transporters in drug development. Annu Rev Pharmacol Toxicol 2012 1.30
24 Comparison of human solute carriers. Protein Sci 2010 1.29
25 Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003 1.29
26 Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A 2011 1.29
27 Functional genomics of membrane transporters in human populations. Genome Res 2005 1.27
28 A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res 2011 1.26
29 Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov 2008 1.24
30 Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002 1.24
31 The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther 2008 1.23
32 Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009 1.18
33 Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 2010 1.17
34 The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am J Physiol Renal Physiol 2005 1.15
35 Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 2010 1.10
36 The role of ATM in response to metformin treatment and activation of AMPK. Nat Genet 2012 1.06
37 Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1. Proc Natl Acad Sci U S A 2013 1.06
38 Novel variants in human Aquaporin-4 reduce cellular water permeability. Hum Mol Genet 2008 1.04
39 Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenet Genomics 2010 1.03
40 Consequences of POR mutations and polymorphisms. Mol Cell Endocrinol 2010 1.03
41 Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 2007 1.02
42 Selecting optimum eukaryotic integral membrane proteins for structure determination by rapid expression and solubilization screening. J Mol Biol 2008 1.02
43 Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res 2011 1.02
44 Functional genetic variation in the basal promoter of the organic cation/carnitine transporters OCTN1 (SLC22A4) and OCTN2 (SLC22A5). J Pharmacol Exp Ther 2009 1.01
45 Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 2003 1.01
46 Functional genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol Pharmacol 2006 1.00
47 Identification and characterization of novel polymorphisms in the basal promoter of the human transporter, MATE1. Pharmacogenet Genomics 2009 1.00
48 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol 2008 0.99
49 Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations. Mol Pharmacol 2004 0.99
50 Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics 2005 0.98
51 Genetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variation. PLoS One 2009 0.96
52 Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther 2010 0.96
53 Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther 2010 0.96
54 Molecular modeling and ligand docking for solute carrier (SLC) transporters. Curr Top Med Chem 2013 0.95
55 Genetic variation in human P450 oxidoreductase. Mol Cell Endocrinol 2008 0.95
56 High selectivity of the γ-aminobutyric acid transporter 2 (GAT-2, SLC6A13) revealed by structure-based approach. J Biol Chem 2012 0.94
57 Identification and characterization of proximal promoter polymorphisms in the human concentrative nucleoside transporter 2 (SLC28A2). J Pharmacol Exp Ther 2008 0.94
58 Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003 0.93
59 Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology 2008 0.93
60 Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells. Am J Physiol Renal Physiol 2003 0.92
61 A survey of integral alpha-helical membrane proteins. J Struct Funct Genomics 2009 0.89
62 PharmGKB update: I. Genetic variants of the organic cation transporter 2 (OCT2, SLC22A2). Pharmacol Rev 2003 0.89
63 Characterizing the dose-response relationship between mannitol and intracranial pressure in traumatic brain injury patients using a high-frequency physiological data collection system. J Neurotrauma 2008 0.87
64 The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. J Cardiovasc Pharmacol 2009 0.86
65 Genetic analysis and functional characterization of polymorphisms in the human concentrative nucleoside transporter, CNT2. Pharmacogenet Genomics 2005 0.86
66 Interaction of sirolimus and everolimus with hepatic and intestinal organic anion-transporting polypeptide transporters. Xenobiotica 2011 0.83
67 Genetic variation in human aquaporins and effects on phenotypes of water homeostasis. Hum Mutat 2008 0.83
68 Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates. Am J Physiol Renal Physiol 2010 0.81
69 Role of aromatic transmembrane residues of the organic anion transporter, rOAT3, in substrate recognition. Biochemistry 2002 0.81
70 Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. Mol Biosyst 2010 0.81
71 Haplotype structure and ethnic-specific allele frequencies at the OCTN locus: implications for the genetics of Crohn's disease. Inflamm Bowel Dis 2005 0.81
72 Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res 2010 0.81
73 Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics 2010 0.80
74 Institutional Profile: The University of California Pharmacogenomics Center: at the interface of genomics, biological mechanisms and drug therapy. Pharmacogenomics 2009 0.80
75 Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures. Mol Pharm 2013 0.80
76 Functional characterization and haplotype analysis of polymorphisms in the human equilibrative nucleoside transporter, ENT2. Drug Metab Dispos 2005 0.79
77 GABAA receptor open-state conformation determines non-competitive antagonist binding. Toxicol Appl Pharmacol 2010 0.79
78 PharmGKB submission update: IV. PMT submissions of genetic variations in ATP-Binding cassette transporters to the PharmGKB network. Pharmacol Rev 2006 0.79
79 A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome. Pharmacogenet Genomics 2015 0.78
80 PharmGKB update: III. Genetic variants of SLC22A1, solute carrier family 22 (organic cation transporter), member 1. Pharmacol Rev 2004 0.78
81 Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia. J Hum Genet 2013 0.78
82 SLC19A1 pharmacogenomics summary. Pharmacogenet Genomics 2010 0.78
83 Sorting of rat SPNT in renal epithelium is independent of N-glycosylation. Pharm Res 2003 0.78
84 Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong! Pharm Res 2012 0.78
85 Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8). J Pharm Sci 2013 0.78
86 SNP analysis and presentation in the Pharmacogenetics of Membrane Transporters Project. Pac Symp Biocomput 2003 0.77
87 Special Section on Pharmacogenomics: recent advances and future directions. J Hum Genet 2013 0.76
88 OCT1 in hepatic steatosis and thiamine disposition. Cell Cycle 2015 0.76
89 Specificity of human and rat orthologs of the concentrative nucleoside transporter, SPNT. Am J Physiol Renal Physiol 2002 0.75
90 Molecular determinants of specificity for synthetic nucleoside analogs in the concentrative nucleoside transporter, CNT2. J Biol Chem 2006 0.75
91 Enhancing data sharing in collaborative research projects with DASH. Pac Symp Biocomput 2005 0.75
92 Computational Discovery And Experimental Validation of Inhibitors of the Human Intestinal Transporter, OATP2B1. J Chem Inf Model 2017 0.75
93 PharmGKB submission update: VI. PMT submissions of genetic variations in neurotransmitter transporters (SLC6, SLC17, and SLC18) to the PharmGKB network. Pharmacol Rev 2006 0.75
94 PharmGKB summary: very important pharmacogene information for ABCG2. Pharmacogenet Genomics 2017 0.75
95 PharmGKB submission update: V. PMT submissions of genetic variation in SLC22 family transporters. Pharmacol Rev 2006 0.75